Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia ( vol 122 , 106946, 2022)

被引：0
|
作者：
Klink, Andrew J. [1 ]
Gajra, Ajeet [1 ]
Knoth, Russell L. [2 ]
Marshall, Landon [1 ]
Hou, Ying [1 ]
McBride, Ali [2 ]
Copher, Ronda [2 ]
机构：
[1] Cardinal Hlth Specialty Solut, 7000 Carinal Pl, Dublin, OH USA
[2] Brystol Meyers Squibb, 86 Morris Ave, Summit, NJ 10154 USA
来源：
LEUKEMIA RESEARCH | 2024年 / 136卷
关键词：
D O I：
10.1016/j.leukres.2023.107430
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia
    Klink, Andrew J.
    Gajra, Ajeet
    Knoth, Russell L.
    Marshall, Landon
    Hou, Ying
    McBride, Ali
    Copher, Ronda
    LEUKEMIA RESEARCH, 2022, 122
  • [2] Real-World Use of Enasidenib in Relapsed or Refractory Acute Myeloid Leukemia Is Associated with Reduced Risk of Disease Progression and Death
    Klink, Andrew J.
    Copher, Ronda
    Knoth, Russell L.
    Marshall, Landon
    Hou, Ying
    Gajra, Ajeet
    Tibes, Raoul
    BLOOD, 2020, 136
  • [3] Outcomes of patients with relapsed or refractory acute myeloid leukemia: a population-based real-world study
    Brandwein, Joseph M.
    Saini, Lalit
    Geddes, Michelle N.
    Yusuf, Dimas
    Liu, Fei
    Schwann, Kiersten
    Billawala, Alkarim
    Westcott, Christopher
    Kurniawan, Jessica A.
    Cheung, Winson Y.
    AMERICAN JOURNAL OF BLOOD RESEARCH, 2020, 10 (04): : 124 - 133
  • [4] A Real-World Study on Clofarabine and Cytarabine Combination in Patients with Relapsed/Refractory Acute Myeloid Leukemia
    Crobu, Valeria
    Caocci, Giovanni
    La Nasa, Giorgio
    Saderi, Laura
    Sotgiu, Giovanni
    Fozza, Claudio
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2019, 11
  • [5] Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia - A Retrospective Study of a Real-World Setting
    Saiz-Rodriguez, Miriam
    Cuevas, Beatriz
    Alvarez, Rodolfo
    Cuello, Rebeca
    Belen Vidriales, Maria
    Olivier, Carmen
    Recio, Isabel
    Campuzano, Veronica
    Yeguas, Ana
    Cuevas, Victoria
    Javier Diaz-Galvez, Francisco
    Ruano, Teresa
    Avendano, Alejandro
    Duenas, Veronica
    Garcia, Covadonga
    Jose Gonzalez-Lopez, Tomas
    Olazabal, Juan
    Serra, Fe
    De Vicente, Pilar
    Hermida, Gerardo
    Labrador, Jorge
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2020, 20 : S173 - S174
  • [6] Real-World Outcomes of Relapsed/Refractory Core-Binding Factor Acute Myeloid Leukemia: A COMMAND Registry Study
    Rojek, Alexandra E.
    Mccormick, Benjamin J.
    Cwykiel, Joanna
    Odetola, Oluwatobi
    Abaza, Yasmin
    Nai, Nhi
    Foucar, Charles E.
    Achar, Rohan K.
    Shallis, Rory M.
    Bradshaw, Danielle
    Standridge, Meaghan
    Kota, Vamsi
    Murthy, Guru Subramanian Guru
    Badar, Talha
    Patel, Anand A.
    AMERICAN JOURNAL OF HEMATOLOGY, 2025,
  • [7] Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia
    Stein, Eytan M.
    DiNardo, Courtney D.
    Pollyea, Daniel A.
    Fathi, Amir T.
    Roboz, Gail J.
    Altman, Jessica K.
    Stone, Richard M.
    DeAngelo, Daniel J.
    Levine, Ross L.
    Flinn, Ian W.
    Kantarjian, Hagop M.
    Collins, Robert
    Patel, Manish R.
    Frankel, Arthur E.
    Stein, Anthony
    Sekeres, Mikkael A.
    Swords, Ronan T.
    Medeiros, Bruno C.
    Willekens, Christophe
    Vyas, Paresh
    Tosolini, Alessandra
    Xu, Qiang
    Knight, Robert D.
    Yen, Katharine E.
    Agresta, Sam
    de Botton, Stephane
    Tallman, Martin S.
    BLOOD, 2017, 130 (06) : 722 - 731
  • [8] Prospective Real-World Outcomes of Acute Myeloid Leukemia
    Karakus, Volkan
    Iltar, Utku
    Yenihayat, Emel Merve
    Polat, Merve Gokcan
    Celik, Serhat
    Malkan, Umit Yavuz
    Seval, Guldane Cengiz
    Dogan, Ali
    Akdeniz, Aydan
    Pinar, Ibrahim Ethem
    Ozdalci, Demircan
    Ince, Idris
    Erdem, Ramazan
    Mehtap, Ozgur
    Kirkizlar, Hakki Onur
    Kacmaz, Murat
    Deveci, Burak
    Aykas, Fatma
    Akat, Gulten Korkmaz
    Kaya, Sureyya Yigit
    Ozturk, Hacer Berna Afacan
    Sevindik, Omur
    Can, Ferda
    Cekdemir, Demet
    Aslan, Ceyda
    Bulbul, Hale
    Guven, Zeynep Tugba
    Maral, Senem
    Durusoy, Salih Sertac
    Demirkan, Fatih
    Goker, Hakan
    Ozkalemkas, Fahir
    Keklik, Muzaffer
    Toprak, Selami Kocak
    Yucel, Elcin Erdogan
    Atas, Unal
    Alacacioglu, Inci
    BLOOD, 2023, 142
  • [9] Enasidenib for the treatment of relapsed or refractory acute myeloid leukemia with an isocitrate dehydrogenase 2 mutation
    Heiblig, Mael
    Hachem-Khalife, Sabine
    Willekens, Christophe
    Micol, Jean-Baptiste
    Paci, Angelo
    Penard-Lacronique, Virginie
    de Bottona, Stephane
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2020, 5 (06): : 421 - 428
  • [10] Real-world results of venetoclax combined with hypomethylating agents in young adults with relapsed/refractory acute myeloid leukemia
    Xu, Xuezhu
    Liu, Rui
    He, Aili
    Wang, Fangxia
    HEMATOLOGY, 2023, 28 (01)
12345